Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1997-9-15
|
pubmed:abstractText |
The antihypertensive effects of oral or intravenous administration of AE0047, a novel 1,4-dihydropyridine-type calcium antagonist, were investigated in spontaneously hypertensive rats (SHR/crj), one kidney-one clip renal hypertensive rats (RHR), deoxycorticosterone acetate (DOCA)-salt hypertensive rats (DHR) and two kidney-one clip renal hypertensive dogs (RHD). AE0047 (1, 3, 10 mg/kg, p.o.) caused a dose-related reduction of systolic blood pressure (SBP) with low reflex tachycardia in SHR/crj and RHR. The effect reached its maximum at 2-4 hr after administration and was sustained for a long time. In DHR, AE0047 (0.3, 1, 3 mg/kg, p.o.) similarly showed the antihypertensive effects at 2-7 hr with no significant changes in heart rates (HR). The doses (ED30) of AE0047 required to decrease SBP by 30% were 2.6, 3.4 and 0.68 mg/kg in SHR/crj, RHR and DHR, respectively. In RHD, and AE0047 capsule (GJ-0956: 4, 8, 16, 32 mg/body, p.o.) produced dose-dependent and long lasting effects with a transient and slight increase in HR. Furthermore, the intravenous administration of AE0047 (10, 30, 100 micrograms/kg) produced the antihypertensive action slowly, reached a plateau 10 min later and then maintained for many hours. In contrast, nitrendipine (3-100 mg/kg, p.o., 3-30 micrograms/kg, i.v.) and nicardipine (1-30 mg/kg, p.o., 3-30 micrograms/kg, i.v.) exhibited a similar potency to AE0047, but these maximal effects were produced at 1-2 hr and 0.5-1 min in the case of oral and intravenous administration, respectively, with a rapid recovery in the above hypertensive rats. These results indicate that AE0047 exhibits an antihypertensive effect with a slow onset and long-lasting profile.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AE0047,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Desoxycorticosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydropyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Nicardipine,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrendipine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0015-5691
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
109
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
279-89
|
pubmed:dateRevised |
2011-7-27
|
pubmed:meshHeading |
pubmed-meshheading:9253775-Administration, Oral,
pubmed-meshheading:9253775-Animals,
pubmed-meshheading:9253775-Antihypertensive Agents,
pubmed-meshheading:9253775-Blood Pressure,
pubmed-meshheading:9253775-Calcium Channel Blockers,
pubmed-meshheading:9253775-Desoxycorticosterone,
pubmed-meshheading:9253775-Dihydropyridines,
pubmed-meshheading:9253775-Dogs,
pubmed-meshheading:9253775-Dose-Response Relationship, Drug,
pubmed-meshheading:9253775-Heart Rate,
pubmed-meshheading:9253775-Hypertension,
pubmed-meshheading:9253775-Hypertension, Renal,
pubmed-meshheading:9253775-Injections, Intravenous,
pubmed-meshheading:9253775-Nicardipine,
pubmed-meshheading:9253775-Nitrendipine,
pubmed-meshheading:9253775-Rats,
pubmed-meshheading:9253775-Rats, Inbred SHR
|
pubmed:year |
1997
|
pubmed:articleTitle |
[Antihypertensive effects of a novel calcium antagonist, AE0047, in various hypertensive models].
|
pubmed:affiliation |
Central Research Laboratories, Green Cross Corporation, Osaka, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|